Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib
Aim: To assess real-world clinical outcomes in patients with non-small-cell lung cancerwith MET exon 14 skipping mutation and brain metastases (BM) who received capmatinib, a recently approved MET inhibitor, in routine US clinical practice. Materials & methods: Patient data were collected using a retrospective medical record review, led by participating oncologists. Eligible patients initiated treatment with capmatinib in any line, after BM diagnosis, between May 2020 and June 2021. Data on real-worldoverall response rate (rwORR) and real-world progression-free survival (rwPFS) were descriptively analyzed. Results: 68 eligible patients were analyzed. In patients treated with first-line (1L) capmatinib (n=55), the rwORR was 90.9% systemically and 87.3% intracranially; median systemic rwPFS was 14.1months. Among radiation-naive patients on 1L capmatinib (n=20), rwORR was 85.0%, both systemically and intracranially; median systemic rwPFS was 14.1months. Conclusion: This study showed substantial systemic and intracranial effectiveness for capmatinib in real-world setting; findings were consistent for RT-naive patients. We evaluated #realworld outcomes for patients with #NSCLC with METex14 mutation and brain metastases, treated with capmatinib in clinical practice. We found substantial systemic and intracranial effectiveness with first-line capmatinib therapy.
Authors
- Keith L. Davis (ORCID: https://orcid.org/0000-0002-0044-7107)
- Paul K. Paik (ORCID: https://orcid.org/0000-0002-9464-3984)
- Mark A Price (ORCID: https://orcid.org/0000-0002-9831-4328)
- Teddy Rassem Saliba
- Beilei Cai (ORCID: https://orcid.org/0000-0002-2762-3908)
- Valérie Derrien Ansquer (ORCID: https://orcid.org/0000-0002-0606-975X)
- RK Goyal (ORCID: https://orcid.org/0000-0003-1632-036X)
- Nydia Caro
Publication Details
- Journal
- Figshare
- Published
- 2026-11-13
- DOI
- https://doi.org/10.6084/m9.figshare.35003952
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00